BackPhio Pharmaceuticals - Warrants (21/12/2021) Overview

Phio Pharmaceuticals - Warrants (21/12/2021) Net Tangible Assets

Phio Pharmaceuticals - Warrants (21/12/2021)'s net tangible assets is $13M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$12.60M
↑ 24.83% YoYΔ $2.51M vs prior year quarter

Peer trimmed avg / median

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) Net Tangible Assets History

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) vs. peers: Net Tangible Assets Comparison

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) (PHIOW) FAQ

Phio Pharmaceuticals - Warrants (21/12/2021) posts a net tangible assets of $13M as of June 2026. That compares with $10M in the prior-year period — up 24.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Phio Pharmaceuticals - Warrants (21/12/2021)'s net tangible assets was $10M. The latest reading is $13M — a 24.8% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Net Tangible Assets is one piece of Phio Pharmaceuticals - Warrants (21/12/2021)'s financial statement story. At $13M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PHIOW's net tangible assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Phio Pharmaceuticals - Warrants (21/12/2021)'s other metric pages and overview cover the third.

Judging Phio Pharmaceuticals - Warrants (21/12/2021) against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in net tangible assets easier to interpret. Start with $13M here, then scan peer and history charts to see if the gap is persistent.